Stock Code: 000028/200028 Notice No.: 2022-23
Short Form of the Stock: Sinopharm Accord /Accord B
China National Accord Medicines Corporation Ltd.
The First Quarterly Report for 2022
The Company and whole members of the BOD guarantee that the information disclosed is true,
accurate and complete, and there are no any fictitious records, misleading statements or important
omissions.
Important content reminder:
1. Board of Directors, Supervisory Committee, all directors, supervisors and senior executives of China National
Accord Medicines Corporation Ltd. (hereinafter referred to as the Company) hereby confirm that there are no any
fictitious statements, misleading statements, or important omissions carried in this report, and shall take all
responsibilities, individual and/or joint, for the reality, accuracy and completion of the whole contents.
2. Principal of the Company, Person in Charge of Accounting Works and Person in Charge of Accounting Organ
(Accounting Officer) hereby confirm that the Financial Report of the First Quarterly Report is authentic, accurate
and complete.
3. Whether the First Quarterly Report has been audited or not
□Yes √No
I. Main financial data
(i) Main accounting data and financial indexes
Whether it has retroactive adjustment or re-statement on previous accounting data or not
□Yes√ No
Changes of this period over
Current Period Same period of last year
same period of last year
Operating income (RMB) 17,150,856,946.54 16,049,966,325.75 6.86%
Net profit attributable to shareholders of
252,361,872.69 328,800,560.24 -23.25%
the listed company (RMB)
Net profit attributable to shareholders of
the listed company after deducting 242,244,636.06 321,593,612.98 -24.67%
non-recurring gains and losses (RMB)
Net cash flow arising from operating
-217,452,223.38 -306,748,999.24 29.11%
activities (RMB)
Basic earnings per share (RMB/Share) 0.59 0.77 -23.38%
Diluted earnings per share (RMB/Share) 0.59 0.77 -23.38%
Weighted average ROE 1.68% 2.33% 0.65 percentage points
1
down
Changes of this period-end
End of this period End of last period over same period-end of last
year
Total assets (RMB) 44,844,103,338.63 42,783,682,431.81 4.82%
Owners’ equity attributable to shareholders
15,177,183,542.81 14,924,938,052.50 1.69%
of listed company (RMB)
Explanation on the business performance and financial status:
The Company achieved operation income of 17,151 million yuan for the first quarter of 2022, a year-on-year increase of 6.86%;
operation profit was 375 million yuan, 20.42% down from a year earlier; the net profit attributable to shareholder of listed company
was 252 million yuan, decrease of 23.25% on a year-on-year basis, the basic EPS decreased by 23.38% correspondingly and
weighted ROE decreased by 0.65 percentage points. Profit decline mainly due to the impact of COVID-19, the performance from
affiliates declined and the investment earnings decreased accordingly. Meanwhile, the customer flow from retail segment drops due
to the epidemic, and the new stores operated in 2021 have a large initial investment, the benefits are not yet visible with shrinking
profit space.
The distribution segment has an operation income of 12,171 million yuan, a year-on-year growth of 7.45%; net profit was 210
million yuan, a year-on-year increase of 10.40%. the retail segment has 5,238 million yuan from the operation income, a year-on-year
increase of 5.11% and achieved a net profit of 32 million yuan, down 63.80% on a year-on-year basis.
(ii) Items of non-recurring gains and losses
√ Applicable □ Not applicable
Unit: RMB/CNY
Item Current amount Note
The gains on disposal of
Gains/losses from the disposal of non-current asset (including the
785,738.83 right-to-use asses arising from
write-off that accrued for impairment of assets)
off-lease in the period
Governmental subsidy calculated into current gains and
losses(while closely related with the normal business of the Mainly the various special
Company, the government subsidy that accord with the provision 15,562,891.34 subsidies and tax rebates received
of national policies and are continuously enjoyed in line with a in the Period
certain standard quota or quantity are excluded)
Reversal of the account receivable depreciation reserves subject
1,632,768.34
to separate impairment test
Other non-operating income and expenses other than the above 1,205,854.08
Other gains/losses items that meet the definition of non-recurring
1,789,818.44
gains/losses
Less: impact on income tax 5,104,445.81
Impact on minority shareholders’ equity (post-tax) 5,755,388.59
Total 10,117,236.63 --
Details of other gains/losses items that meet the definition of non-recurring gains/losses:
□ Applicable √ Not applicable
2
There are no other gains/losses items that meet the definition of non-recurring gains/losses in the Company.
Explain the items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A
Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss
□ Applicable √ Not applicable
There are no items defined as recurring profit (gain)/loss according to the lists of extraordinary profit (gain)/loss in Q&A
Announcement No.1 on Information Disclosure for Companies Offering Their Securities to the Public --- Extraordinary Profit/loss
(iii) Particulars about material changes in items of main accounting statement and financial index and explanations of
reasons
√ Applicable □Not applicable
(1)Receivable financing: decrease of 557.8708 million yuan from beginning of the Period with a growth rate of -54.31%, mainly due
to the increase in discounting of bank acceptance in the Period;
(2) Construction in progress: decrease of 15.0976 million yuan from beginning of the Period with a growth rate of -30.29%, mainly
because the ERP project transfer-out after completion & acceptance;
(3) Short-term borrowings: increase of 1,108.1141 million yuan from beginning of the Period with a growth rate of 57.40%, mainly
due to the increase in financing with the invoice of account payable;
(4) Employee benefits payable: decrease of 114.3872 million yuan from beginning of the Period with a growth rate of -33.62%,
mainly because the wages and bonuses accrued in the prior year are paid in the Period;
(5) Other incomes: a year-on-year increase of 11.3852 million yuan with a growth rate of 83.37%, mainly because various subsidies
received in the Period and the tax relief increased on a year-on-year basis;
(6) Investment income: a year-on-year decrease of 67.8440 million yuan with a growth rate of -74.30%, mainly because the
performance from affiliates declined and the investment earnings decreased accordingly;
(7) Credit impairment losses: a year-on-year increase of 8.7011 million yuan with a growth rate of 50.60%, mainly due to the
increase of account receivable at period-end compared to the same period of last year for the sales up; affected by the epidemic,
medical insurance allocation was delayed, the capital operation from hospital are relatively tight which had a certain impact on the
receivable collection of the Company, turnover days of the receivable increase to some extent, than the bad debt provision goes up
correspondingly;
(8) Impairment losses: a year-on-year decrease of 1.8342 million yuan with a growth rate of -52.58%, mainly due to the decrease in
provision for inventory falling price reserves on a year-on-year basis;
(9) Gain on disposal of assets: a year-on-year increase of 0.7065 million yuan with a growth rate of 259.86%, mainly due to the
increase in earnings on a year-on-year basis, resulting from disposal of the right-of-use assets for vacating from retail stores.
(10)Non-operating income: a year-on-year decrease of 4.0821 million yuan with a growth rate of -64.08%, mainly because in the
Period, the payable without payment requirements written off declined from a year earlier;
(11) Non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a growth rate of -30.20%, mainly because the
net profit attributable to owners of parent company from subsidiary-Sinopharm Holding Guoda Drugstore Co., Ltd.(hereinafter
referred to as Guoda Drugstore) declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the
strategic investor of the Group-Walgreens Boots Alliance(Hong Kong)Investments Limited (hereinafter referred to as WBA)
decreased on a year-on-year basis;
(12) Total comprehensive income attributable to non-controlling interests: a year-on-year decrease of 18.3534 million yuan with a
growth rate of -30.20%, mainly because the net profit attributable to owners of parent company from subsidiary-Guoda Drugstore
declined on a year-on-year basis, accordingly, the gains/losses of minority attributable to the strategic investor of the Group- WBA
decreased on a year-on-year basis;
(13) Receipts of taxes and surcharges refunds: a year-on-year decrease of 4.7192 million yuan with a growth rate of -84.00%, mainly
3
due to the year-on-year decline in enterprise income tax refunds received in the Period;
(14) Other cash receipts relating to operating activities: a year-on-year decrease of 64.1937 million yuan with a growth rate of
-30.61%, mainly because the reserve funds for epidemic-specific, deposits and security deposit received in the Period declined from a
year earlier;
(15) Cash receipts from returns of investments: a year-on-year decrease of 2.9974 million yuan with a growth rate of -100.00%,
mainly because in same period of last year, received the withdrawal payment from part of the projects of Sinopharm Zhongjin
Medical Industry Fund, and there was no such matter occurred in the Period;
(16) Cash received from investment income: a year-on-year decrease of 3.5996 million yuan with a growth rate of -100.00%, mainly
because in same period of last year, received dividend payment from projects of Sinopharm Zhongjin Medical Industry Fund, and
there was no such matter occurred in the Period;
(17) Net cash receipts from disposal of fixed assets, intangible assets and other long-term assets: a year-on-year decrease of 0.2423
million yuan with a growth rate of -74.08%, mainly because the cash received in the Period from fixed assets disposal decreased
from a year earlier;
(18) Total cash inflows from investing activities: a year-on-year decrease of 6.8393 million yuan with a growth rate of -98.78%,
mainly because in same period of last year, received dividend payment and withdrawal payment from projects of Sinopharm
Zhongjin Medical Industry Fund, and there were no such matters occurred in the Period;
(19) Cash payments for investments: a year-on-year decrease of 8.7574 million yuan with a growth rate of -32.34%, mainly because
the payment for rental transfer fees in the Period declined from a year earlier, paid by subsidiary - Guoda Drugstore;
(20) Net cash payments for acquisition of subsidiaries and other business units: a year-on-year decrease of 73.1595 million yuan with
a growth rate of -100.00%, mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a
subsidiary, and there was no such matter occurred in the Period;
(21) Total cash outflows from investing activities: a year-on-year decrease of 67.8542 million yuan with a growth rate of -41.83%,
mainly because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no
such matter occurred in the Period;
(22) Net cash flows from investing activities: a year-on-year increase of 61.0148 million yuan with a growth rate of 39.29%, mainly
because in same period of last year, subsidiary Guoda Drugstore paid for the acquisition of a subsidiary, and there was no such matter
occurred in the Period;
(23) Cash proceeds from investments by others: a year-on-year decrease of 4.98 million yuan with a growth rate of -84.69%, mainly
due to the year-on-year decrease in investment received from minority during the Period;
(24) Other cash receipts relating to financing activities: a year-on-year decrease of 192.0255 million yuan with a growth rate of
-64.56%, mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis;
(25) Cash repayments for debts: a year-on-year increase of 94.2452 million yuan with a growth rate of 53.17%, mainly due to the
increase in repayment of loans due in the Period;
(26) Total cash outflows from financing activities: a year-on-year increase of 161.1150 million yuan with a growth rate of 33.41%,
mainly because repayment of loans from financial institutions and the rents paid for increasing retail stores in the Period increased on
a year-on-year basis;
(27) Net cash flows from financing activities: a year-on-year decrease of 276.5162 million yuan with a growth rate of -71.17%,
mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rents
paid for increasing retail stores in the Period increased on a year-on-year basis;
(28) Effect of foreign exchange rate changes on cash and cash equivalents: a year-on-year increase of 1,989.89 yuan with a growth
rate of 81.53%, mainly due to the change of exchange rates;
(29) Net increase of cash and cash equivalents :a year-on-year decrease of 126.2026 million yuan with a growth rate of -171.70%,
mainly because in the Period, the recovery of factoring business and repayment difference declined on a year-on-year basis, the rents
paid for increasing retail stores in the Period increased on a year-on-year basis.
4
II. Shareholders
(i) Total number of common shareholders and preference shareholders with voting rights recovered and
top ten shareholders
Unit: Share
Total preference shareholders
Total number of common
with voting rights recovered at
shareholders at the end of report 44,112 0
end of reporting period (if
period
applicable)
Top ten shareholders
Amount of Information of shares pledged,
Shareholder’s Nature of Proportion of Amount of shares
lock-up shares tagged or frozen
name shareholder shares held held
held State of share Amount
Sinopharm Group State-owned
56.06% 239,999,991 5,505,770
Co., Ltd. Corporation
FIRST SENTIER
INVESTORS
GLOBAL
UMBRELLA Foreign
2.52% 10,802,495
FUND PLC - Corporation
FSSA CHINA
GROWTH
FUND
Hong Kong
Securities Foreign
2.28% 9,751,340
Clearing Corporation
Company Ltd.
China National
Pharmaceutical State-owned
1.24% 5,323,043
Foreign Trade Corporation
Corp.
National Social Domestic non
Security Fund state-owned 1.07% 4,590,032
413 Portfolio Corporation
BBH BOS S/A
FIDELITY FD - Foreign
0.78% 3,358,761
CHINA FOCUS Corporation
FD
Fidelity
Foreign
Investment 0.54% 2,301,737
Corporation
Management
5
(Hong Kong)
Limited - Client’s
fund
ICBC-Guolian
Andesheng Domestic non
Small Selected state-owned 0.38% 1,632,000
Securities Corporation
Investment Fund
CPIC Fund
-China Pacific
Life Insurance
Co., Ltd. -
with-profit
insurance- CPIC
Domestic non
Fund China
state-owned 0.34% 1,470,224
Pacific Life
Corporation
Equity Relative
Income
(Guaranteed
Dividend) single
assets
management plan
VANGUARD
EMERGING
Foreign
MARKETS 0.34% 1,456,150
Corporation
STOCK INDEX
FUND
Top ten shareholders with unrestricted shares held
Type of shares
Shareholder’s name Amount of unrestricted shares held
Type Amount
RMB ordinary
Sinopharm Group Co., Ltd. 234,494,221 234,494,221
shares
FIRST SENTIER INVESTORS Domestically
GLOBAL UMBRELLA FUND PLC 10,802,495 listed foreign 10,802,495
- FSSA CHINA GROWTH FUND shares
Hong Kong Securities Clearing RMB ordinary
9,751,340 9,751,340
Company Ltd. shares
China National Pharmaceutical RMB ordinary
5,323,043 5,323,043
Foreign Trade Corp. shares
National Social Security Fund 413 RMB ordinary
4,590,032 4,590,032
Portfolio shares
6
Domestically
BBH BOS S/A FIDELITY FD -
3,358,761 listed foreign 3,358,761
CHINA FOCUS FD
shares
Fidelity Investment Management RMB ordinary
2,301,737 2,301,737
(Hong Kong) Limited - Client’s fund shares
ICBC-Guolian Andesheng Small RMB ordinary
1,632,000 1,632,000
Selected Securities Investment Fund shares
CPIC Fund -China Pacific Life
Insurance Co., Ltd. - with-profit
insurance- CPIC Fund China Pacific RMB ordinary
1,470,224 1,470,224
Life Equity Relative Income shares
(Guaranteed Dividend) single assets
management plan
Domestically
VANGUARD EMERGING
1,456,150 listed foreign 1,456,150
MARKETS STOCK INDEX FUND
shares
Sinopharm Group Co., Ltd. and China National Pharmaceutical Foreign Trade Corporation
Explanation on associated have the same actual controller, which is China National Pharmaceutical Group Corporation.
relationship among the aforesaid It is unknown that there exists no associated relationship or belongs to the consistent actionist
shareholders among the other tradable shareholders regulated by the Management Measure of Information
Disclosure on Change of Shareholding for Listed Companies.
(ii) Total shareholders with preferred stock held and shares held by top ten shareholders with preferred
stock held
□ Applicable √ Not applicable
III. Other important matters
□ Applicable √ Not applicable
IV. Quarterly financial statements
(i) Financial statement
1. Consolidate Balance Sheet
Prepared by China National Accord Medicines Corporation Ltd.
March 31, 2022
Unit: RMB/CNY
Item Ending balance Opening balance
Current assets:
Cash and bank balances 4,867,544,893.18 5,126,159,080.94
Settlement provisions
Capital lent
Trading financial assets
7
Derivative financial assets
Notes receivable 642,430,566.93 680,196,380.57
Accounts receivable 18,445,260,411.58 15,964,603,345.91
Receivable financing 469,356,116.33 1,027,226,940.21
Advances to suppliers 477,599,161.72 520,930,545.31
Insurance receivable
Reinsurance receivables
Contract reserve of reinsurance receivable
Other receivables 654,794,241.77 718,089,129.10
Including: Interest receivable
Dividend receivable
Buying back the sale of financial assets
Inventories 8,058,564,605.96 7,621,541,595.08
Contract assets 29,728,855.46 29,061,159.52
Assets held for sale
Non-current asset due within one year
Other current assets 140,830,256.92 160,607,355.66
Total current assets 33,786,109,109.85 31,848,415,532.30
Non-current assets:
Loans and payments on behalf
Debt investment
Other debt investment
Long-term account receivable
Long-term equity investments 2,501,295,548.16 2,459,832,546.74
Other equity instruments investment 62,488,312.99 62,488,312.99
Other non-current financial assets 135,974,908.51 135,974,908.51
Investment properties 112,808,525.33 113,981,497.23
Fixed assets 850,200,561.56 868,626,258.43
Construction in progress 34,751,943.39 49,849,506.70
Productive biological asset
Oil and gas asset
Right-of-use assets 2,664,487,497.37 2,575,240,340.00
Intangible assets 678,354,661.52 669,926,562.82
Expense on Research and Development
Goodwill 2,775,645,585.32 2,775,645,585.32
Long-term prepaid expenses 621,061,288.02 633,975,441.76
Deferred tax assets 154,699,087.40 129,740,169.77
Other non-current assets 466,226,309.21 459,985,769.24
Total non-current assets t 11,057,994,228.78 10,935,266,899.51
Total assets 44,844,103,338.63 42,783,682,431.81
Current liabilities:
Short-term borrowings 3,038,581,281.11 1,930,467,146.38
Loan from central bank
Capital borrowed
Trading financial liability
Derivative financial liability
8
Notes payable 6,759,000,854.12 7,660,216,823.68
Accounts payable 10,610,876,048.40 9,057,718,968.14
Receipts in advance 18,591,112.89 19,289,567.44
Contract liabilities 429,473,280.23 431,303,231.37
Selling financial asset of repurchase
Absorbing deposit and interbank deposit
Security trading of agency
Security sales of agency
Employee benefits payable 225,809,878.05 340,197,125.33
Tax payable 307,116,334.60 337,164,080.19
Other payables 1,907,708,455.77 1,714,746,986.46
Including: Interest payable 37,765,231.34 31,587,062.03
Dividend payable 30,140,616.33 30,140,616.33
Commission charge and commission payable
Reinsurance payable
Liability held for sale
Non-current liabilities due within one year 851,459,913.02 848,328,648.14
Other current liabilities 37,309,563.28 39,585,469.65
Total current liabilities 24,185,926,721.47 22,379,018,046.78
Non-current liabilities:
Insurance contract reserve
Long-term borrowings 70,137,173.89 71,637,173.89
Bonds payable
Including: Preferred stock
Perpetual capital securities
Lease liabilities 1,420,668,973.13 1,375,427,877.28
Long-term payables 6,938,189.00 6,938,189.00
Long-term employee benefits payable 1,202,000.00 1,202,000.00
Provisions
Deferred income 85,016,983.16 86,917,051.78
Deferred tax liabilities 172,433,335.41 175,948,328.93
Other non-current liabilities 584,974,923.18 664,381,065.65
Total non-current liabilities 2,341,371,577.77 2,382,451,686.53
Total liabilities 26,527,298,299.24 24,761,469,733.31
Equity
Share capital 428,126,983.00 428,126,983.00
Other equity instrument
Including: Preferred stock
Perpetual capital securities
Capital surplus 4,371,621,053.65 4,371,802,107.43
Less: Inventory shares
Other comprehensive income 21,938,869.76 21,874,198.36
Reasonable reserve
Surplus reserve 214,063,491.50 214,063,491.50
Provision of general risk
Retained earnings 10,141,433,144.90 9,889,071,272.21
9
Total equity attributable to owners of the parent 15,177,183,542.81 14,924,938,052.50
Non-controlling interests 3,139,621,496.58 3,097,274,646.00
Total equity 18,316,805,039.39 18,022,212,698.50
Total liabilities and equity 44,844,103,338.63 42,783,682,431.81
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
2. Consolidated Profit Statement
Unit: RMB/CNY
Item Current period Last period
I. Total operating income 17,150,856,946.54 16,049,966,325.75
Including: Operating revenue 17,150,856,946.54 16,049,966,325.75
Interest income
Insurance gained
Commission charge and
commission income
II. Total operating cost 16,797,706,856.47 15,663,170,079.60
Including: Operating costs 15,227,900,206.53 14,260,591,404.46
Interest expense
Commission charge and commission
expense
Cash surrender value
Net amount of expense of compensation
Net amount of withdrawal of insurance contract
reserve
Bonus expense of guarantee slip
Reinsurance expense
Tax and surcharges 41,939,571.15 33,744,327.20
Selling expenses 1,203,497,011.57 1,080,543,941.75
Administrative expenses 264,532,679.98 237,615,927.36
R&D expense
Finance costs 59,837,387.24 50,674,478.83
Including: Interest expenses 72,514,879.45 68,683,688.49
Interest income 16,770,723.32 18,058,735.03
Add: other incomes 25,040,832.98 13,655,624.72
Investment income (Loss is listed with
23,461,476.68 91,305,476.74
“-”)
Including: Investment income from
41,579,383.80 92,441,826.44
associates
Income from the derecognition
of financial assets measured at amortised cost -18,117,907.12 -4,735,905.31
(Loss is listed with “-”)
Exchange income (Loss is listed with
“-”)
10
Net exposure hedging income (Loss is
listed with “-”)
Income from change of fair value (Loss
is listed with “-”)
Credit impairment losses/ (Loss is listed
-25,898,207.09 -17,197,080.80
with “-”)
Impairment losses (Loss is listed with
-1,654,289.70 -3,488,500.85
“-”)
Gain on disposal of assets (Loss is listed
978,407.63 271,889.26
with “-”)
III. Operating profits (Loss is listed with “-”) 375,078,310.57 471,343,655.22
Add: Non-operating income 2,288,693.57 6,370,834.89
Less: Non-operatingexpenses 600,906.15 570,737.09
IV. Total profit (Loss is listed with “-”) 376,766,097.99 477,143,753.02
Less: Income tax expenses 81,994,493.36 87,580,022.00
V. Net profit (Net loss is listed with “-”) 294,771,604.63 389,563,731.02
(i) Classify by business continuity
1. Profit or loss from continuing operations
294,771,604.63 389,563,731.02
(net loss listed with ‘-”)
2.termination of net profit (net loss listed
with ‘-”)
(ii) Classify by ownership
1. Owners of the parent 252,361,872.69 328,800,560.24
2. Non-controlling interests 42,409,731.94 60,763,170.78
VI. Other comprehensive income, net of tax 64,671.40 84,503.76
Other comprehensive income, net of tax,
64,671.40 84,503.76
attributable to owners of the parent
(i) Other comprehensive income items which
will not be reclassified subsequently to profit of
loss
1.Changes of the defined benefit
plans that re-measured
2.Other comprehensive income under
equity method that cannot be transfer to gain/loss
3.Change of fair value of investment
in other equity instrument
4.Fair value change of enterprise's
credit risk
5. Other
(ii) Other comprehensive income that will
64,671.40 84,503.76
be reclassified to profit or loss
1. Other comprehensive income
using the equity method that may be reclassified 64,671.40 84,503.76
to profit or loss
2.Change of fair value of other debt
investment
3.Amount of financial assets
re-classify to other comprehensive income
4.Credit impairment provision for
other debt investment
5.Cash flow hedging reserve
6.Translation differences arising on
11
translation of foreign currency financial
statements
7.Other
Net after-tax of other comprehensive income
attributable to minority shareholders
VII. Total comprehensive income 294,836,276.03 389,648,234.78
Total comprehensive income attributable to
252,426,544.09 328,885,064.00
owners of the parent
Total comprehensive income attributable to
42,409,731.94 60,763,170.78
non-controlling interests
VIII. Earnings per share:
(i) Basic earnings per share 0.59 0.77
(ii) Diluted earnings per share 0.59 0.77
Enterprise combine under the same control in the Period, the combined party realized net profit of 0.00 Yuan before combination, and
realized 0.00 Yuan at last period for combined party.
Legal Representative: Lin Zhaoxiong
Person in charge of accounting works: Gu Guolin
Person in charge of accounting institute: Wang Ying
3. Consolidated Cash Flow Statement
Unit: RMB/CNY
Item Current period Last period
I. Cash flows from operating activities:
Cash received from sales of good or rendering of
16,757,405,030.62 15,194,724,502.12
services
Net increase of customer deposit and interbank
deposit
Net increase of loan from central bank
Net increase of capital borrowed from other financial
institution
Cash received from original insurance contract fee
Net cash received from reinsurance business
Net increase of insured savings and investment
Cash received from interest, commission charge and
commission
Net increase of capital borrowed
Net increase of returned business capital
Net cash received by agents in sale and purchase of
securities
Receipts of taxes and surcharges refunds 898,760.75 5,617,976.11
Other cash receipts relating to operating activities 145,551,765.30 209,745,502.46
Total cash inflows from operating activities 16,903,855,556.67 15,410,087,980.69
Cash payments for goods and services 15,413,374,469.33 14,094,028,880.65
Net increase of customer loans and advances
Net increase of deposits in central bank and
interbank
12
Cash paid for original insurance contract
compensation
Net increase of capital lent
Cash paid for interest, commission charge and
commission
Cash paid for bonus of guarantee slip
Cash payments to and on behalf of employees 999,525,639.18 894,497,321.19
Payments of all types of taxes and surcharges 416,425,915.99 354,054,737.85
Other cash payments relating to operating activities 291,981,755.55 374,256,040.24
Total cash outflows from operating activities 17,121,307,780.05 15,716,836,979.93
Net cash flows from operating activities -217,452,223.38 -306,748,999.24
II. Cash flows from investing activities:
Cash receipts from returns of investments 2,997,441.73
Cash received from investment income 3,599,555.61
Net cash receipts from disposal of fixed assets,
84,789.95 327,119.50
intangible assets and other long-term assets
Net cash received from disposal of subsidiaries and
other units
Other cash receipts relating to investing activities
Total cash inflows from investing activities 84,789.95 6,924,116.84
Cash payments to acquire fixed assets, intangible assets
76,023,361.87 61,960,648.98
and other long-term assets
Cash payments for investments 18,322,350.00 27,079,733.00
Net increase of mortgaged loans
Net cash payments for acquisition of subsidiaries and
73,159,498.29
other business units
Cash payments related to other investing activities
Total cash outflows from investing activities 94,345,711.87 162,199,880.27
Net cash flows from investing activities -94,260,921.92 -155,275,763.43
III. Cash flows from financing activities
Cash proceeds from investments by others 900,000.00 5,880,000.00
Incl: Cash receipts from capital contributions from
900,000.00 5,880,000.00
non-controlling interests of subsidiaries
Cash receipts from borrowings 649,000,000.00 567,395,696.23
Other cash receipts relating to financing activities 105,391,223.35 297,416,755.19
Total cash inflows from financing activities 755,291,223.35 870,692,451.42
Cash repayments for debts 271,500,000.00 177,254,802.73
Cash payments for distribution of dividends or profit
63,873,455.61 59,139,307.66
and interest expenses
Incl: Dividends or profit paid to non-controlling
962,881.36 555,825.80
shareholders of subsidiaries
Other cash payments relating to financing activities 307,909,948.17 245,774,326.14
Total cash outflows from financing activities 643,283,403.78 482,168,436.53
Net cash flows from financing activities 112,007,819.57 388,524,014.89
IV. Effect of foreign exchange rate changes on cash and
-450.89 -2,440.78
cash equivalents
V. Net increase of cash and cash equivalents -199,705,776.62 -73,503,188.56
Add: Cash and cash equivalents at beginning of the
4,733,512,172.37 5,405,113,257.99
year
VI. Cash and cash equivalents at end of year 4,533,806,395.75 5,331,610,069.43
13
(ii) Audit report
Whether the 1st quarterly report has been audited or not
□Yes √ No
The 1st quarterly report of the Company has not been audited.
China National Accord Medicines Corporation Ltd.
Legal representative: Lin Zhaoxiong
April 28, 2022
14
